Abstract:Background and objectives: Cognitive impairment is a frequent nonmotor symptom in patients with Parkinson disease (PD), and early cognitive decline is often attributed to dopaminergic system dysfunction. We aimed to explore spatiotemporal progression patterns of striatal dopamine availability and regional brain volume based on cognitive status among patients with PD. Methods: This retrospective, cross-sectional study included patients with newly diagnosed PD who were not taking medication for this condition who visited a university-affiliated hospital in Seoul between January 2018 and December 2020. Patients were classified as having normal cognition (PD-NC), mild cognitive impairment (PD-MCI), or PD dementia (PDD) based on Seoul Neuropsychological Screening Battery-II, which includes 31 subsets covering activities of daily living and 5 cognitive domains. They all had brain imaging with MRI and PET with 18F-N-(3-fluoropropyl)-2beta-carbon ethoxy-3beta-(4-iodophenyl) nortropane at baseline. Subsequently, standardized uptake value ratios (SUVRs) for regional dopamine availability and regional gray matter volumes were obtained using automated segmentation. These metrics were compared across cognitive status groups, and spatiotemporal progression patterns were analyzed using the Subtype and Stage Inference machine learning technique. Results: Among 168 patients (mean age, 73.3 ± 6.1 years; 81 [48.2%] women), 65 had PD-NC, 65 had PD-MCI, and 38 had PDD. Patients with PD-MCI exhibited lower SUVRs (3.61 ± 1.31, p < 0.001) in the caudate than patients with PD-NC (4.43 ± 1.21) but higher SUVRs than patients with PDD (2.39 ± 1.06). Patients with PD-NC had higher thalamic SUVRs (1.55 ± 0.16, p < 0.001) than patients with both PD-MCI (1.45 ± 0.16) and PDD (1.38 ± 0.19). Regional deep gray matter volumes of the caudate (p = 0.015), putamen (p = 0.012), globus pallidus (p < 0.001), thalamus (p < 0.001), hippocampus (p < 0.001), and amygdala (p < 0.001) were more reduced in patients with PD-MCI or PDD than in patients with PD-NC, and the SUVR of the caudate correlated with caudate volume (r = 0.187, p = 0.015). Hippocampal atrophy was the initial change influencing cognitive impairment. The reduced dopamine availability of the thalamus preceded reductions in volume across most deep gray matter regions. Discussion: Our finding underscores the association between decreased dopamine availability and volume of the caudate and thalamus with cognitive dysfunction in PD. The dopamine availability of the caudate and thalamus was reduced before the volume of the caudate and thalamus was decreased, highlighting the spatiotemporal association between dopaminergic and structural pathology in cognitive impairment in PD.

Monoaminergic degeneration, cognition, and autonomic symptom trajectory in early Parkinson's disease

Monoaminergic Degeneration and Ocular Motor Abnormalities in De Novo Parkinson's Disease

Spatiotemporal Neurodegeneration of the Substantia Nigra and Its Connecting Cortex and Subcortex in Parkinson's Disease.

Convergence of striatal monoaminergic degeneration and CSF A beta 42/alpha-synuclein reductions in human Parkinson's disease with possible cognitive decline

The Longitudinal Volumetric and Shape Changes of Subcortical Nuclei in Parkinson’s Disease

Spatiotemporal Progression Patterns of Dopamine Availability and Deep Gray Matter Volume in Parkinson Disease-Related Cognitive Impairment

Symmetric and Profound Monoaminergic Degeneration in Parkinson's Disease with Premotor REM Sleep Behavior Disorder

Progressive Brain Atrophy in Parkinson's Disease Patients Who Convert to Mild Cognitive Impairment.

Serotonergic and Dopaminergic Lesions Underlying Parkinsonian Neuropsychiatric Signs

Predictors associated with the rate of progression of nigrostriatal degeneration in Parkinson's disease

Autonomic dysfunction and white matter microstructural changes in drug-naïve patients with Parkinson’s disease

Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage capacity

Association between Olfactory Deficit and Motor and Cognitive Function in Parkinson’s Disease

Cognitive and Cholinergic Systems Trajectories in Parkinson Disease

Brain Metabolic Correlates of Dopaminergic Denervation in Prodromal and Early Parkinson's Disease

Neuropathobiology of non-motor symptoms in Parkinson disease

Extra-basal ganglia iron content and non-motor symptoms in drug-naïve, early Parkinson’s disease

Impact of olfactory function on the trajectory of cognition, motor function, and quality of life in Parkinson's disease

Autonomic symptoms in early-stage Parkinson’s patients and their relationship with cognition and disease parameters

Patterns of regional cerebral hypoperfusion in early Parkinson's disease: Clinical implications

Comprehensive serum metabolic and proteomic characterization on cognitive dysfunction in Parkinson’s disease